Monitor for COVID-19 vaccine resistance evolution during clinical trials.

Monitor for COVID-19 vaccine resistance evolution during clinical trials.
复制标题

DOI:
10.1371/journal.pbio.3001000
复制
发表时间:
2020-11
期刊:
影响因子:
9.8
通讯作者:
Read AF
Read AF
中科院分区:
生物学1区
文献类型:
--
作者:
Kennedy DA;Read AF

文献摘要

参考文献

被引文献

相似文献

尽管不像抗菌药物耐药性的进化那么常见,但疫苗耐药性可以而且已经进化了。目前正在开发的 COVID-19 疫苗有多大可能会因病毒进化而受到破坏?我们认为,这可以通过重新利用已经作为临床试验一部分收集的样本来确定。此类信息将有助于优先考虑候选疫苗的投资并最大限度地发挥 COVID-19 疫苗的潜在长期影响。安全有效的 COVID-19 疫苗是否会因疫苗耐药性的进化而受到损害?这篇《透视》文章认为,通过重新利用临床试验中已经收集的样本,甚至在疫苗获得许可之前就可以回答这个问题,而不是采取观望态度。
Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-term impact of COVID-19 vaccines. Will a safe and efficacious COVID-19 vaccine be undermined by vaccine-resistance evolution? Rather than take a wait-and-see approach, this Perspective article argues that this question can be answered even before a vaccine is licensed, by repurposing samples already being collected in clinical trials.
DOI: 10.3389/fimmu.2019.00655
发表时间: 2019-04-26
影响因子: 7.3
作者:
Lehmann, Paul, V;Suwansaard, Maneewan;Reche, Pedro A.
通讯作者: Reche, Pedro A.
DOI: 10.1098/rspb.2016.2562
发表时间: 2017-03-29
期刊: Proceedings. Biological sciences
影响因子: --
作者:
Kennedy DA;Read AF
通讯作者: Read AF
DOI: 10.1073/pnas.94.12.6571
发表时间: 1997-06-10
影响因子: 11.1
作者:
Lipsitch, M
通讯作者: Lipsitch, M
DOI: 10.1126/science.abd0831
发表时间: 2020-08-21
期刊: SCIENCE
影响因子: 56.9
作者:
Baum, Alina;Fulton, Benjamin O.;Kyratsous, Christos A.
通讯作者: Kyratsous, Christos A.
DOI: 10.1086/339342
发表时间: 2002-03-15
影响因子: 6.4
作者:
Genton, B;Betuela, I;Alpers, MP
通讯作者: Alpers, MP